DESIGN OF BETA CELL LYMPHOMA-2 (BCL-2) RECEPTOR ANTAGONISTS AS CHEMOTHERAPEUTIC AGENTS

• At: 2019 FIP Congress in AbuDhabi (United Arab Emirates)
• Type: Poster
• By: SHOEMAKE, Claire (University of Malta, Pharmacy, Malta)
• Co-author(s): Yvonne Savona Ventura: Pharmacy, University of Malta, Msida, Malta
  Claire Shoemake: Pharmacy, University of Malta, Msida, Malta
  
• Abstract:

  Background

  The Beta Cell Lymphoma-2 (BCL-2) receptor is a prosurvival protein. It is consequently a target in the design of molecules capable of restoring cells' to perform apoptosis. Navitoclax and venetoclax are BCL-2 antagonists, but are associated with thrombocytopaenic side-effects.

  Methods

  A virtual screening approach was adopted. Bioactive

  ..

The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login